Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Buske C, et al. Among authors: dreyling m. Leukemia. 2009 Jan;23(1):153-61. doi: 10.1038/leu.2008.261. Epub 2008 Sep 25. Leukemia. 2009. PMID: 18818699 Clinical Trial.
Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement.
Klaus M, Schnittger S, Haferlach T, Dreyling M, Hiddemann W, Schoch C. Klaus M, et al. Among authors: dreyling m. Cancer Genet Cytogenet. 2003 Jul 1;144(1):36-43. doi: 10.1016/s0165-4608(02)00876-2. Cancer Genet Cytogenet. 2003. PMID: 12810254
[Prophylaxis and differential therapy of tumorlysis syndrome].
Krych M, Dreyling M, Kneba M, Hoelzer D, Hiddemann W, Hallek M. Krych M, et al. Among authors: dreyling m. Dtsch Med Wochenschr. 2004 Jun 18;129(25-26):1440-5. doi: 10.1055/s-2004-826887. Dtsch Med Wochenschr. 2004. PMID: 15213877 Review. German. No abstract available.
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Lenz G, et al. Among authors: dreyling m. Blood. 2004 Nov 1;104(9):2667-74. doi: 10.1182/blood-2004-03-0982. Epub 2004 Jul 6. Blood. 2004. PMID: 15238420 Free article. Clinical Trial.
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Forstpointner R, et al. Among authors: dreyling m. Blood. 2004 Nov 15;104(10):3064-71. doi: 10.1182/blood-2004-04-1323. Epub 2004 Jul 29. Blood. 2004. PMID: 15284112 Free article. Clinical Trial.
[Monoclonal antibody treatment of malignant lymphoma].
Buske C, Dreyling M, Unterhalt M, Hiddemann W. Buske C, et al. Among authors: dreyling m. Internist (Berl). 2004 Dec;45(12):1370-7. doi: 10.1007/s00108-004-1299-z. Internist (Berl). 2004. PMID: 15517123 Review. German.
456 results